Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients
Melanoma Research, 07/29/09
Homsi J et al. - In a trial to investigate the response rate and safety of weekly docosahexaenoic acid (DHA)-paclitaxel in metastatic melanoma pts, it appears that as single-agent therapy, DHA-paclitaxel was well tolerated in metastatic melanoma pts. Its efficacy as a first-line therapy for metastatic melanoma does not exceed that seen with other single-agent chemotherapies such as dacarbazine.
Methods- Chemotherapy-naive pts with metastatic nonchoroidal melanoma were enrolled using the 2-stage Fleming design.
- At least 1 response was needed in the first stage to proceed to the second stage.
- DHA-paclitaxel (500 mg/m2/wk by 1-h intravenous infusion) was administered for 5 wks every 6-wk cycle until disease progression, intolerable toxicity, or treatment refusal.
- Response and toxicity were assessed every 6 wks and wkly, respectively.
- 30 pts were enrolled; median age was 67 yrs.
- Median number of treatment cycles was 2.
- 3 pts (10%) had partial responses; 1 lasted 4 mos, and 2 lasted 5.6 mos.
- 15 pts (50%) had stable disease with a median duration of 2.8 mos.
- Median survival was 14.8 mos.
- Neutropenia (10%) and musculoskeletal pain (10%) were the most common grade 3 and 4 toxicities, and fatigue (73%), skin rash (70%), and diarrhea (60%) were the most common side effects.
Related Articles
Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy
The Oncologist, 10/30/09
Relevance Score: 70%
Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09
Relevance Score: 70%
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09
Relevance Score: 69%
Dormancy of metastatic melanoma
Pigment Cell & Melanoma Research, 11/11/09
Relevance Score: 68%
Metastatic cutaneous malignant melanoma: Spectrum of imaging findings and the role of multimodality imaging
Journal of Medical Imaging and Radiation Oncology (JMIRO), 10/05/09
Relevance Score: 68%
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling
Oncogene, 12/04/09
Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application
Journal of the European Academy of Dermatology and Venereology, 12/02/09
Self-reported screening for skin cancer in Austria
European Journal of Dermatology, 12/02/09
Sponsor
Article Search
Sponsor
Sponsor